Information Provided By:
Fly News Breaks for August 2, 2016
ESRX, CVS, HZNP
Aug 2, 2016 | 11:45 EDT
BMO Capital analyst Gary Nachman said Horizon Pharma (HZNP) securing covered status for Duexis and Vimovo with CVS/Caremark (CVS) is an "important win" for the drugmaker that demonstrates it is improving its execution on the managed care front. While Express Scripts (ESRX) still has Duexis and Vimovo on its exclusion list for 2017, Horizon indicated that it is still in discussions that have been "constructive," noted Nachman, who keeps an Outperform rating on Horizon shares.
News For HZNP;CVS;ESRX From the Last 2 Days
There are no results for your query HZNP;CVS;ESRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.